Phathom Pharmaceuticals, Inc. PHAT Debt Issuance Cost Amortization
Debt Issuance Cost Amortization at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s debt issuance cost amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s debt issuance cost amortization?
- Phathom Pharmaceuticals, Inc. (PHAT) reported debt issuance cost amortization of $844K in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s debt issuance cost amortization changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s debt issuance cost amortization increased by 21.3% year-over-year, from $696K to $844K.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s debt issuance cost amortization?
- Over 4 years (2021 to 2025), Phathom Pharmaceuticals, Inc.'s debt issuance cost amortization has grown at a -4.3% compound annual growth rate (CAGR), from $3.6M to $3.01M.
- What does debt issuance cost amortization mean?
- Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).